PRESS RELEASE
News
-
-
PRESS RELEASE
Share price target 12.50 euros: Annual General Meeting supports SYNBIOTIC's growth plans with over 99 percent approval
Annual General Meeting of SYNBIOTIC SE garners over 99% approval for growth plans targeting EUR 12.50 share price. Positive outlook fueled by strategic investments and market developments -
PRESS RELEASE
Notice of Extraordinary General Meeting of Shareholders of Multitude P.L.C.
Notice of Extraordinary General Meeting of Shareholders of Multitude P.L.C. to adopt the final accounts and related resolutions following transfer of registered office from Finland to Malta. Meeting on 23 October 2024 in Helsinki, Finland -
-
PRESS RELEASE
Detailed statement by Mutares on the Gotham City research report and the short attack as well as the allegations made therein
Mutares SE & Co. KGaA issues detailed statement in response to Gotham City research report with focus on growth strategy, investments, and financials for the fiscal year 2024 -
-
-
-
PRESS RELEASE
Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
Formycon and Fresenius Kabi secure European Commission approval for FYB202/Otulfi® (ustekinumab) to treat inflammatory diseases, expanding biosimilar portfolio -
